

IPR2018-00717
Patent No. 9,492,393
Declaration of Hossein Omidian, Ph.D.
Attorney Docket No. KASHIV 7.1R-005

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

KASHIV PHARMA, LLC,

Petitioner,

v.

PURDUE PHARMA L.P., and
PURDUE PHARMACEUTICALS L.P.,
Patent Owners.

Patent No. 9,492,393 to McKenna *et al.*
Issue Date: November 15, 2016
Title: TAMPER RESISTANT DOSAGE FORMS

Inter Partes Review No. IPR2018-00717

(Exhibit 1030)

**DECLARATION OF HOSSEIN OMIDIAN, Ph.D. IN SUPPORT
OF *INTER PARTES* REVIEW OF U.S. PATENT NO. 9,492,393**

TABLE OF CONTENTS

	Page
I. INTRODUCTION	1
II. MY BACKGROUND AND QUALIFICATIONS	1
III. THE '393 PATENT.....	5
IV. PERTINENT PROSECUTION HISTORY OF THE '393 PATENT.....	12
V. A PERSON OF ORDINARY SKILL IN THE ART	15
VI. CLAIM CONSTRUCTION	17
A. “Compression Shaped” And “Compression”	18
B. “Air Cured” And “Curing”	18
C. “Optionally”	19
D. “Total Combined Weight Of Said High And Low Molecular Weight PEO”	19
E. Rheological Measurements And Units	20
F. Product-By-Process Limitations	20
VII. TECHNICAL BACKGROUND AND STATE OF THE ART	22
A. Polymer Matrix Extended-Release Strategy.....	24
B. Bartholomaus	34
C. McGinity	36
D. SDNY II Decision.....	37

E. Wright	39
F. Oshlack 2	42
G. Oshlack 3	44
H. Royce	45
I. Moroni.....	45
J. Shao.....	46
K. Zhou	48
VIII. DENSITY	48
A. The Data Does Not Reliably Show Density Decrease	49
B. Purdue Mentions No Advantage Of A Decrease In Density And None Would Be Apparent To A POSA.....	55
C. Even The Art Relied On By The Examiner In Connection With Density Is Inconsistent With A Conclusion That A Density Change Would Be Superior.....	56
IX. GROUND 1	59
X. GROUND 2	74
XI. CONCLUSION.....	86

I, HOSSEIN OMIDIAN, declare and state as follows:

I. INTRODUCTION

1. I am a U.S. citizen and a resident of the State of Florida.

2. I have been retained by Lerner, David, Littenberg, Krumholz & Mentlik, LLP (“counsel”) to provide my opinions in the field of pharmaceutical formulation for purposes of this petition for *Inter Partes* Review (“IPR”). I have read and understand U.S. Patent No. 9,492,393 (“the ’393 Patent”) (Ex. 1001) as well as all other references discussed in this declaration. I am being compensated for my time in an amount consistent with my customary consulting fee, and my compensation is not contingent on my opinion or the outcome of this proceeding. I have provided a declaration in connection with IPR2018-00625 filed February 27, 2018, seeking cancellation of claims of a related patent, U.S. Patent No. 9,492,392.

II. MY BACKGROUND AND QUALIFICATIONS

3. I have about 30 years of experience in both academia and industry.

4. I received my B.Sc. in Chemical Engineering in 1987 and M.Sc. in Polymer Engineering in 1990 from Tehran Polytechnic University in Tehran, Iran. I received my Ph.D. in Polymer Engineering and Science in 1998 from the Brunel University in London, UK. The title of my dissertation was “Improved Superabsorbent Polymers.” Throughout my career, my research interests have

included polymer synthesis and characterization, scale up of polymer products, *in vitro* and *in vivo* preclinical and clinical testing of polymer-based products for pharmaceutical applications, pharmaceutical formulations, advanced pharmaceutical dosage forms for oral targeted drug delivery, abuse deterrent formulations, polymers for pharmaceutical and biomedical applications, immediate and extended-release dosage forms, and developing polymer-based products for hygiene and other industrial applications.

5. I'm currently a full professor of pharmaceutical sciences at the College of Pharmacy of Nova Southeastern University. In this position, I teach several core and elective courses in the professional Pharm.D., Masters, and Ph.D. programs. The courses I teach, or coordinate, include Pharmaceutics I — this course is about utilizing physical chemical principles of materials in developing pharmaceutical dosage forms, Advanced Physical Pharmacy, Pharmaceutical Polymers, Research Techniques and Instrumentation, and Advanced Topics in Pharmaceutical Sciences. Moreover, my lab is conducting research in the area of novel pharmaceutical formulations, in particular, abuse-deterrent dosage forms capable of deterring abuse by injection, insufflation, and oral ingestion. I currently train and supervise several Pharm.D. and Ph.D. students.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.